PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1
- Resource Type
- article
- Source
- Journal for ImmunoTherapy of Cancer, Vol 11, Iss 6 (2023)
- Subject
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 - Language
- English
- ISSN
- 2051-1426
24665983